Total Funding
68
29
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
156245
Gritstone bio is a biotechnology company that develops immunotherapies for cancer and infectious diseases.
Mark Cobbold: Scientific Co-FounderPast Role: Massachusetts General Hospital, Associate Professor- Vijay Yabannavar: Executive Vice President, Manufacturing & Technical Operations
About the Company
Gritstone bio develops immunotherapies for cancer and infectious diseases. They started with tumor-specific neoantigens and their programs to include viral antigens displayed on the surface of the virally infected cells. Their biological immune system recognition of targets on the surface of abnormal cells is common to anti-tumor and anti-viral
immunity. With the development and commercialization of immunotherapy drugs including checkpoint inhibitors, the field of immuno-oncology is transforming the treatment of patients with cancer.
